Steve Beuchaw
Stock Analyst at Morgan Stanley
(2.47)
# 2,382
Out of 4,761 analysts
103
Total ratings
60.87%
Success rate
6.84%
Average return
Main Sectors:
Stocks Rated by Steve Beuchaw
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QGEN Qiagen | Downgrades: Equal-Weight | $52 → $49 | $39.57 | +24.94% | 2 | Jan 6, 2025 | |
| A Agilent Technologies | Initiates: Outperform | n/a | $135.37 | - | 20 | Dec 13, 2023 | |
| ALGN Align Technology | Maintains: Outperform | $711 → $770 | $190.43 | +304.35% | 11 | Jul 29, 2021 | |
| BRKR Bruker | Upgrades: Peer Perform | n/a | $50.82 | - | 9 | Nov 16, 2020 | |
| HSIC Henry Schein | Upgrades: Outperform | $68 | $77.24 | -11.96% | 4 | Apr 2, 2020 | |
| XRAY DENTSPLY SIRONA | Upgrades: Outperform | $66 | $18.75 | +252.00% | 6 | Apr 2, 2020 | |
| ILMN Illumina | Maintains: Equal-Weight | $320 → $288 | $94.20 | +205.73% | 9 | Jan 7, 2019 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $254 → $260 | $532.55 | -51.18% | 7 | Oct 25, 2018 | |
| WAT Waters | Maintains: Equal-Weight | $204 → $211 | $374.82 | -43.71% | 13 | Oct 10, 2018 | |
| MYGN Myriad Genetics | Maintains: Overweight | $51 → $54 | $14.18 | +280.82% | 10 | Oct 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $41 | $162.31 | -74.74% | 5 | Sep 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $335 | $312.05 | +7.35% | 1 | Sep 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $335 | $280.08 | +19.61% | 1 | Sep 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $19 | $31.07 | -38.85% | 5 | Aug 31, 2018 |
Qiagen
Jan 6, 2025
Downgrades: Equal-Weight
Price Target: $52 → $49
Current: $39.57
Upside: +24.94%
Agilent Technologies
Dec 13, 2023
Initiates: Outperform
Price Target: n/a
Current: $135.37
Upside: -
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $711 → $770
Current: $190.43
Upside: +304.35%
Bruker
Nov 16, 2020
Upgrades: Peer Perform
Price Target: n/a
Current: $50.82
Upside: -
Henry Schein
Apr 2, 2020
Upgrades: Outperform
Price Target: $68
Current: $77.24
Upside: -11.96%
DENTSPLY SIRONA
Apr 2, 2020
Upgrades: Outperform
Price Target: $66
Current: $18.75
Upside: +252.00%
Illumina
Jan 7, 2019
Maintains: Equal-Weight
Price Target: $320 → $288
Current: $94.20
Upside: +205.73%
Thermo Fisher Scientific
Oct 25, 2018
Maintains: Overweight
Price Target: $254 → $260
Current: $532.55
Upside: -51.18%
Waters
Oct 10, 2018
Maintains: Equal-Weight
Price Target: $204 → $211
Current: $374.82
Upside: -43.71%
Myriad Genetics
Oct 10, 2018
Maintains: Overweight
Price Target: $51 → $54
Current: $14.18
Upside: +280.82%
Sep 28, 2018
Maintains: Overweight
Price Target: $21 → $41
Current: $162.31
Upside: -74.74%
Sep 20, 2018
Initiates: Equal-Weight
Price Target: $335
Current: $312.05
Upside: +7.35%
Sep 20, 2018
Initiates: Equal-Weight
Price Target: $335
Current: $280.08
Upside: +19.61%
Aug 31, 2018
Maintains: Underweight
Price Target: $21 → $19
Current: $31.07
Upside: -38.85%